In this interview with BioPharm International, Russell Miller, our VP, Global Sales and Marketing, discusses the transformative impact of Enzene’s innovative Fully-Connected Continuous Manufacturing™ technology on the biomanufacturing industry.He explains how EnzeneX™ 2.0 technology is reshaping the production process and highlights the strategic significance of Enzene’s new state-of-the-art facility in New Jersey.
Key takeaways:
◉ Understand the ‘connected’ edge that sets Fully-Connected Continuous Manufacturing™ apart from traditional methods.
◉ Hear about the strategic impact of Enzene’s new facility in New Jersey.
◉ Learn about overcoming the $40-per-gram barrier in monoclonal antibody production with EnzeneX™ 2.0.
0:14 What makes Enzene’s EnzeneX™ platform a winning formula/game-changer?
1:40 How do you see Enzene’s new facility contributing to its global expansion strategy, particularly in the US market?
3:29 How does EnzeneX™ 2.0 tackle cost-efficiency, a critical challenge in biologics manufacturing?
5:22 Who can benefit the most from the fully-connected continuous manufacturing™ technology?
7:09 Looking ahead, what is Enzene’s vision over the next five years?
